Alpine Woods Capital Investors LLC Decreases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Alpine Woods Capital Investors LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% in the second quarter, Holdings Channel reports. The institutional investor owned 2,055 shares of the biopharmaceutical company’s stock after selling 56 shares during the period. Alpine Woods Capital Investors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,079,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of REGN. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 31 shares during the last quarter. Activest Wealth Management lifted its holdings in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Finally, Colonial Trust Advisors purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research analyst reports. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday. Rothschild & Co Redburn initiated coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 target price on the stock. Finally, Wells Fargo & Company cut Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 target price on the stock. in a research report on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $817.88.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $557.73 on Tuesday. The stock has a market capitalization of $59.11 billion, a PE ratio of 14.06, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,024.36. The stock’s 50-day moving average price is $573.67 and its 200 day moving average price is $563.46. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.56 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.